Why Is Actinium Pharmaceuticals Stock Gaining Tuesday?
Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
Share
Why It Matters
Actinium tested a new cancer medicine and early results look safe. When a medicine passes early tests, people get more hopeful about the company.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.